688553.SH
汇宇制药-W
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 12.04
+1.01%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.0B | 998.1M | 1.1B | 927.1M | 1.5B |
| Cost of Revenue | 220.5M | 203.6M | 181.5M | 130.4M | 176.2M |
| Gross Profit | 807.8M | 794.5M | 912.9M | 796.6M | 1.3B |
| Operating Expenses | |||||
| R&D Expense | 307.7M | 302.7M | 327.7M | 340.8M | 356.2M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 102.7M | 97.1M | 80.5M | 76.5M | 71.8M |
| Selling & Marketing Expense | 352.3M | 359.2M | 431.1M | 361.1M | 739.1M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 736.1M | 720.2M | 825.1M | 743.3M | 1.1B |
| Cost and Expenses | 956.6M | 923.8M | 1.0B | 873.7M | 1.3B |
| Operating Income (EBIT) | (6.4M) | (66.2M) | 348.4M | 124.4M | 235.4M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (4.7M) | (64.3M) | 349.7M | 132.2M | 238.4M |
| Income Tax Expense | (22.5M) | (33.8M) | 33.8M | (7.2M) | (10.6M) |
| Bottom Line | |||||
| Net Income | 22.5M | (25.0M) | 325.4M | 139.8M | 249.0M |
| Earnings from Cont. Ops | 17.9M | (30.5M) | 315.9M | 139.3M | 249.0M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 22.5M | (25.0M) | 325.4M | 139.8M | 249.0M |
| Per Share | |||||
| Basic EPS | CN¥0.05 | (CN¥0.06) | CN¥0.77 | CN¥0.33 | CN¥0.59 |
| Diluted EPS | CN¥0.05 | (CN¥0.06) | CN¥0.77 | CN¥0.33 | CN¥0.59 |
| Revenue Per Share | CN¥2.35 | CN¥2.40 | CN¥2.59 | CN¥2.19 | CN¥3.54 |
| Shares | |||||
| Basic Shares Outstanding | 437.4M | 416.0M | 422.6M | 423.6M | 422.0M |
| Diluted Shares Outstanding | 437.4M | 416.0M | 422.6M | 423.6M | 422.0M |
| Profitability Metrics | |||||
| EBITDA | — | 24.5M | 426.7M | 183.9M | 283.2M |
| D&A | — | 90.8M | 78.2M | 59.5M | 47.7M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026